INTRODUCTION
============

Ischemic stroke, a devastating neurological disease, is the third leading cause of death and permanent disability in adults all over the world ([@b23-bt-25-272]). Reperfusion to the ischemic brain is currently the best way of salvaging ischemic brain and limiting infarct development ([@b25-bt-25-272]). However, ischemia-reperfusion injury (IRI) is generally believed to be another significant clinical problem in treatment of cerebral damage. In addition, the exactly pathogenesis of cerebral IRI is not yet completely understood. Accumulating evidence has demonstrated that inflammation ([@b14-bt-25-272]; [@b23-bt-25-272]), reactive oxygen species (ROS) ([@b36-bt-25-272]; [@b29-bt-25-272]), and apoptosis ([@b11-bt-25-272]; [@b12-bt-25-272]; [@b30-bt-25-272]) are involved in IRI. Moreover, many signaling pathways have been reported to be associated with the pathogenesis of cerebral IRI, including mitogen-activated protein kinase (MAPK) ([@b21-bt-25-272]). Therefore, numerous investigations have been paid attention to inhibit the inflammation, ROS, apoptosis, and/or MAPK pathway as targets of neuroprotection.

Fucoidan, a sulfated polysaccharide, is mainly found in various species of brown algae and brown seaweed and is now used as an ingredient in some dietary supplement products. In recent years, it has gained a great deal of attention due to its wide range of pharmacological properties, such as anti-tumor ([@b22-bt-25-272]; [@b28-bt-25-272]), antioxidant and anti-coagulant ([@b39-bt-25-272]), anti-viral ([@b34-bt-25-272]; [@b38-bt-25-272]) and anti-inflammatory ([@b8-bt-25-272]). Fucoidan has been used to treat many health conditions, including myocardial and renal IRI ([@b1-bt-25-272]; [@b24-bt-25-272]). However, little information is available regarding the effect of fucoidan on cerebral IRI.

Therefore, in the present study, we aimed to investigate the effect of fucoidan on cerebral IRI, as well as the underlying mechanisms. The rats were pre-treated with 80 mg/kg or 160 mg/kg fucoidan for 7 days before the model of cerebral IRI was induced. After administration of fucoidan, we evaluated infarct volume, neurological deficit scores, and the levels of inflammation-associated cytokines, oxidative stress-related proteins, apoptosis-related proteins and MAPK pathway proteins. Our results might provide new strategies to improve the treatment of cerebral IRI.

MATERIALS AND METHODS
=====================

Preparation of fucoidan
-----------------------

Crude fucoidan was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). Fucoidan was dissolved in physiological saline to 20 mg/mL for animal treatment, and stored at −20°C until for later analysis.

Animals and experimental designs
--------------------------------

Adult male Sprague-Dawley (SD) rats weighing between 250 and 320 g were purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences (Shanghai, China). All the animals were allowed to acclimate to the laboratory conditions for at least 1 week before the test. The animals were housed individually under standard conditions (12:12 h light-dark cycle, 20--22°C, and 50--65% humidity), with food and water *ad libitum*. The rats were randomly divided into four groups (n = 10 in each group): sham-operated group (Sham); IRI+saline group (IRI+S); IRI+80 mg/kg fucoidan group (IRI+F80); and IRI+160 mg/kg fucoidan group (IRI+F160). Fucoidan (80 mg/kg or 160 mg/kg) was intraperitoneally injected from 7 days before MCAO until sacrifice. In sham-operated rats, the arteries were separated without occlusion. The rats in the IRI+S group received physiological saline as control. All experimental protocols were carried out in accordance with the Principles of Laboratory Animal Care and approved by the Ethics Committee of Shaanxi Traditional Chinese Medicine Hospital (Xi'an, Shaanxi, China).

Induction of focal cerebral ischemia and reperfusion in rats
------------------------------------------------------------

Focal brain ischemia-reperfusion was induced by intraluminal MCAO as described previously with minor modifications ([@b5-bt-25-272]). Briefly, the rats were anesthetized and then a midline neck incision was performed under a stereo dissecting microscope (Nikon, Tokyo, Japan). After carefully separated the left common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA), the proximal left CCA and the ECA were ligated. A 5-0 monofilament suture (Harvard Apparatus, Holliston, MA, USA) was introduced through a small arteriotomy of the CCA into the distal ICA and was advanced 9--10 mm distal to the origin of middle cerebral artery (MCA) until the MCA was occluded. The suture was withdrawn from the carotid artery to ensure the reperfusion. Then, the wound was closed. The rectal temperature was maintained at 36.5--37.5°C with a homeothermic temperature system (Fine Science Tools Inc., Foster City, CA, USA) during the surgical procedure and up to 24 h after reperfusion. Twenty-four hours after reperfusion, the rats were euthanized by cervical dislocation under anesthesia with 5% isoflurane.

Evaluation of neurological deficits and determination of infarct volume
-----------------------------------------------------------------------

Neurological deficits were evaluated at 24 h after reperfusion by a neurological scoring system: 0 represents normal spontaneous movement; 1 represents failure to extend the contra lateral forelimb; 2 represents circling to affected side; 3 means partial paralysis on affected side; and 4 presents no spontaneous motor activity. The rats were killed at 24 h after MCAO under anesthesia. The brains were immediately collected, frozen, sectioned into coronal slices, incubated with 2% 2,3,5-triphenyltetrazolium chloride monohydrate (TTC) at 37°C for 15 min, and then maintained in 4% paraformaldehyde overnight. The brain slices were photographed and the total infarct volume was calculated.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

The secreted levels of interleukin (IL)-1β, IL-6, myeloperoxidase (MPO), tumor necrosis factor (TNF)-α, malondialdehyde (MDA), and superoxide dismutase (SOD) in the ischemic brain were measured by a commercially available ELISA kits (R&D System, Minneapolis, MN, USA) according to the manufacturer's instructions. The absorbance at 450 nm was read on a microplate reader (Molecular Devices Corp., Sunnyvale, CA, USA).

Western blot analysis
---------------------

Protein was extracted from the brain issues, and the concentrations of protein were measured by BCA protein assay kit (Beyotime Institute of Biotechnology, Shanghai, China). The protein samples were separated by sodium dodecyl sulfonate (SDS) polyacrylamide gel electrophoresis, and blotted to polyvinylidene difluoride (PVDF) membranes. Blots were were blocked in 5% non-fat dried milk and incubated with antibodies against Bax, B-cell lymphoma (Bcl)-2, phosphorylationextracellular signal-regulated kinase (p-ERK), ERK, p- c-Jun N-terminal kinase (JNK), JNK, p-p38, p38, p-p53, and p53. All antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Then the bolts were incubated with goat anti-rabbi IgG for 2 h at room temperature, and detected by enhanced chemiluminescence and densitometric analysis. Densitometric values were normalized to the GAPDH control.

Statistical analysis
--------------------

All data were shown as the mean ± SD. Statistical Package for the Social Sciences (SPSS) (version 18.0, SPSS Inc., Chicago, IL, USA) was performed to compare the significance of the differences among different groups. Student's *t* test or a one-way analysis of variance (ANOVA) was carried out to calculate *p*-values. Differences were considered significant when *p*\<0.05.

RESULTS
=======

Effects of fucoidan on infarct volume
-------------------------------------

To evaluate the functional role of fucoidan in IRI in rats, we first administrated different doses of fucoidan (80 mg/kg or 160 mg/kg) to the rats and then induced the IRI model by MCAO method. The infarct volume was determined after administration of fucoidan. The representative photographs of brain tissues were shown in [Fig. 1A](#f1-bt-25-272){ref-type="fig"}, whereas the quantitative evaluation result were shown in [Fig. 1B](#f1-bt-25-272){ref-type="fig"}. Form these pictures, we found that administration of 80 mg/kg fucoidan significantly reduced the infarct volume compared to the IRI+S group (*p*\<0.01), and while administration of 160 mg/kg fucoidan further significantly decreased the infarct volume compared to the IRI+S group (*p*\<0.001), indicating that fucoidan might protect against IRI in a dose-dependent manner.

Effects of fucoidan on neurological deficit score
-------------------------------------------------

After successful induction of IRI by MCAO method, we evaluated the effect of fucoidan on neurological deficit score. The results showed that in the sham group, rats appeared with non-neurological impairment symptoms, in contrast, rats in the IRI+S group showed significantly increased the neurological deficit scores compared to the Sham group (neurological score: 3.2 ± 0.84 *vs* 0.2 ± 0.04, *p*\<0.05). However, administration of fucoidan (80 mg/kg or 160 mg/kg) significantly decreased the neurological deficit scores (neurological score: 2.2 ± 0.83 or 1.6 ± 0.89) compared to the IRI+S group (both *p*\<0.05, [Fig. 2](#f2-bt-25-272){ref-type="fig"}). These data indicated that treatment with fucoidan can significantly ameliorate these neurological impairment symptoms after cerebral ischemic injury in rats.

Effects of fucoidan on inflammation-associated cytokines
--------------------------------------------------------

There is ample evidence that inflammatory-associated cytokines such as IL-1β, IL-6, and TNF-α, play a chief role in inflammatory cerebral IRI injury ([@b43-bt-25-272]). MPO is a marker that indicates tissue infiltration of inflammatory cells ([@b4-bt-25-272]). In this study, ELISA was performed to measure the content of IL-1β, IL-6, MPO, and TNF-α. As shown in [Fig. 3](#f3-bt-25-272){ref-type="fig"}, the results showed that the levels of IL-1β, IL-6, MPO, and TNF-α were all significantly decreased by treatment with fucoidan compared with the IRI+S group (*p*\<0.05 for F80 and *p*\<0.01 for F160). The results demonstrated that fucoidan can significantly relieve the inflammatory response after cerebral ischemic injury in rats.

Effects of fucoidan on oxidative stress-related proteins
--------------------------------------------------------

It has been well demonstrated that oxidative stress is involved in the pathogenesis of cerebral IRI ([@b41-bt-25-272]). Therefore, we evaluated the effect of fucoidan on oxidative stress-related protein SOD, and MDA. The levels of SOD and MDA were measured by ELISA. As shown in [Fig. 4](#f4-bt-25-272){ref-type="fig"}, we observed that treatment with fucoidan significantly decreased the levels of SOD and MDA compared with the IRI+S group (*p*\<0.05 for F80 and *p*\<0.01 for F160). Our data indicated that fucoidan can significantly alleviate the oxidative stress response after cerebral ischemic injury in rats.

Effects of fucoidan on apoptosis-related proteins and MAPK pathway
------------------------------------------------------------------

Neuronal apoptosis plays a significant role in neuronal loss after IRI, which is mediated by apoptosis-specific genes, oncogens, or anti-ongogens, such as Bcl-2, Bax, and p53 ([@b44-bt-25-272]). Hence, the effect of fucoidan on apoptosis-related protein was investigated. As shown in [Fig. 5A and 5B](#f5-bt-25-272){ref-type="fig"}, the representative photographs of Western blot showed that both the levels of p-p53 and Bax were significantly higher while the levels of Bcl-2 were markedly lower after IRI. However, administration of fucoidan statistically reduced the levels of p-p53 and Bax but obviously elevated the levels of Bcl-2 (*p*\<0.05 for F80 and *p*\<0.01 for F160). In addition, high concentration of fucoidan exerted different effects on the levels of apoptosis-related proteins, indicating a dose-dependent manner. Further, we explored the effect of fucoidan on MAPK pathway by determining the protein levels of p38, ERK, JNK, and their phosphorylated status. Our results showed that all the levels of p-p38, p-ERK, and p-JNK were significantly decreased by administration of fucoidan in a dose-independent way (*p*\<0.05 for F80 and *p*\<0.01 for F160) ([Fig. 5C, 5D](#f5-bt-25-272){ref-type="fig"}). The data suggested that fucoidan played a protective role in cerebral IRI might be by inhibition of MAPK signaling pathway.

DISCUSSION
==========

In the present study, we explored the effect of fucoidan on cerebral IRI. The results showed that administration of fucoidan significantly decreased the neurological deficit scores and infarct volume. Also, fucoidan statistically changed the levels of inflammation-associated cytokines (IL-1β, IL-6, MPO, and TNF-α), oxidative stress-related protein SOD, and MDA, apoptosis-related proteins (p-p53, Bax and Bcl-2). These data indicated that fucoidan potently protected the brain from IRI injury and this protection may be mediated by MAPK signaling pathway.

Fucoidan is a complex of sulfated polysaccharide found in several different species of brown seaweed, such as bladder wrack and kelp. Fucoidan contains a large proportion of L-fucose and sulfate that are significantly contributed to its potential health benefits. Fucoidan has been reported a broad spectrum of biological activities and is used medicinally for a wide variety of health purposes. Many studies have showed that fucoidan showed a protective role in IRI. For example, Bojakowski and co-workers found that administration of fucoidan significantly increased postischemic renal blood flow and is beneficial to renal IRI ([@b1-bt-25-272]). [@b24-bt-25-272] revealed that the administration of fucoidan could regulate the inflammation response by inactivation of nuclear factor (NF)-κB inactivation in IRI-induced myocardial damage. Omata and co-workers suggested fucoidan exerted a protective role in myocardial IRI by blockade of P-selectin-mediated neutrophil rolling on the vessel wall ([@b32-bt-25-272]). Moreover, accumulating evidence has suggested that fucoidan has neuroprotective actions ([@b13-bt-25-272]; [@b16-bt-25-272], [@b18-bt-25-272], [@b17-bt-25-272]). Although the relatively large size of fucoidan precludes penetration of blood brain barrier (BBB), systemic administration of fucoidan has been reported to be effective in maintaining brain function *in vivo* and *in vitro* in a number of ways. [@b15-bt-25-272] suggested that fucoidan blocked β-amyloid protein (Aβ)-induced decrease in whole-cell currents in basal forebrain neurons and showed neuroprotective effects against Aβ-induced neurotoxicity in basal forebrain neuronal cultures. [@b7-bt-25-272] found that fucoidan was able to protect against lipopolysaccharide (LPS)-induced nitric oxide (NO) production by microglia. Besides, Fucoidan is an inhibitor of Aβ binding to the type A macrophage scavenger receptor (SR-A) ([@b9-bt-25-272]), and blocking the SR-A by fucoidan presents neuro-protective effects. For example, [@b26-bt-25-272] demonstrated that *Fucus vesiculosis* fucoidan (40 ng/mL) suppressed uptake of fragmented DNA (fDNA) by adjacent activated microglia in neuronal nuclei in Alzheimer brain. Therefore, we speculated that fucoidan might play a protective role in cerebral IRI.

To ensure the speculation, we first administered different doses of fucoidan to the rats for continuous 7 days before the cerebral IRI was induced. After 24 h of reputation, the neurological deficit scores and infarct volume were evaluated. The data showed that pre-treatment with fucoidan significantly reduced both the neurological deficit scores and infarct volume compared to the rats received saline. Also, with higher dose of fucoidan, better outcome was observed. Our results indicated that fucoidan might play a protective role in cerebral IRI. To explore the underlying mechanisms, we focused on the anti-inflammatory, antioxidant and anti-apoptotic effects of fucoidan.

Inflammatory responses are characterized by hyper-expression of inflammatory cytokines and neutrophil infiltration into ischemic brain after injury, which play a vital role in the pathogenesis of cerebral ischemic damage ([@b40-bt-25-272]; [@b37-bt-25-272]). The inflammatory process is driven by various cytokines, such as IL-1β, IL-6 and TNF-α ([@b42-bt-25-272]; [@b27-bt-25-272]; [@b31-bt-25-272]). MPO is neutrophil-derived enzyme and a marker of neutrophil activation, which is considered as a biochemical marker for tissue invasion or content of neutrophils ([@b4-bt-25-272]). It has been reported that fucoidan significantly reduced the expression levels of IL-1β, IL-1 and TNF-α during lipopolysaccharide (LPS)-induced inflammation in RAW264.7 cells ([@b20-bt-25-272]). Also, MPO activity was significantly decreased by administration of fucoidin after rat heart IRI ([@b32-bt-25-272]; [@b24-bt-25-272]; [@b6-bt-25-272]). In our study, fucoidan also significantly decreased the levels of IL-1β, IL-1 and TNF-α and MPO activity in cerebral IRI with a dose-dependent manner, indicating an anti-inflammatory effect. Antioxidants, such as SOD, play critical roles in reversing the pathological damage caused by IRI ([@b33-bt-25-272]). [@b6-bt-25-272] found that fucoidin corrected the abnormal levels of MPO, MDA and SOD induced by IRI. Our results also found that pre-treatment with fucoidin statistically decreased the levels of SOD and MDA, suggesting an antioxidant effect. Apoptosis induced by extrinsic pathway or intrinsic pathway has been well involved in cerebral IRI ([@b3-bt-25-272]). The Bcl-2 family members play significant roles in the mitochondria-dependent intrinsic pathway of apoptosis. Overexpression of Bcl-2 enhances cell survival by inhibiting apoptosis, whereas Bax, a member of the Bcl-2 family proteins, promotes apoptosis and counter plays the protective effect of Bcl-2 ([@b3-bt-25-272]). In addition, p53, the tumor-suppressor transcription factor, stops the cell cycle and triggers programmed cell death by promoting the expression of pro-apoptotic protein and suppressing the expression of anti-apoptotic protein ([@b35-bt-25-272]). Our data showed that fucoidin statistically reduced the levels of p-p53 and Bax but elevated Bcl-2, exerting a protective effect on inhibition of brain cells. Our results were similar with the researches of Boo and Chen. [@b2-bt-25-272] found that fucoidan reduced Bcl-2 expression, but increased Bax expression in a dose-dependent fashion in A549 human lung carcinoma cells. [@b6-bt-25-272] observed that pre-treatment with fucoidin remarkably inhibited the phosphorylation of p53, leading to a protective effect on myocardial cells. Moreover, the effects of fucoidin on a verity of human diseases have been reported to be involved in many signaling pathways, such as MAPK pathway ([@b10-bt-25-272]; [@b6-bt-25-272]). Additionally, MAPK pathway is responsible for cerebral IRI ([@b21-bt-25-272]). JNK and p38 are mainly activated through environmental stresses, such as oxidative stress, and inflammatory cytokine, while ERK is normally involved in cell proliferation and growth ([@b19-bt-25-272]). Activation of MAPKs stimulates transcription factors that regulate multiple genes involved in the survival or death of cells, and thus the transcription factors play significant roles in pharmacological intervention and drug development. When the rats were exposed to MCAO in our study, a drastic and rapid increase in phosphorylation of JNK, p38 and ERK was found. Pre-treatment with fucoidin resulted in decreased phosphorylation of all three molecules. Therefore, fucoidin inhibited the activation of MAPK pathway.

In conclusion, our results suggest that fucoidin plays a protective role in cerebral IRI, and these effects might be through inhibition of MAPK pathway.
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